Business Lines
OWL Genomics has developed a technological platform that systematically combines innovative technology in genomics, proteomics, metabolomics and bioinformatics with the aim of developing early diagnosis systems, searching therapeutic targets and providing a complete metabolomic service to external organizations.
Currently there are two business lines:
- In vitro serum based diagnosis products:
- owl liver: owl liver is the first serum based test to be used for Steatosis and NASH diagnosis. It is an innovative non-invasive method that allows the diagnosis through the identification and validation of metabolomic and proteomic biomarkers.
- Product Pipeline: OWL Genomics is currently applying its know-how in metabolomic technology to other diseases with complex diagnostics with a personalized medicine approach..
- R & D Projects development to external organizations: OWL Genomics offers metabolomic services to pharmaceutical and biotechnology companies in key areas such as biomarkers discovery, clinical studies, diagnostics and toxicology.
OWL Genomics strives to provide a top quality service for cutting-edge research, using strictly controlled analytical procedures and state of the art facilities under expert supervision.
- From a multi-technological approach, becoming a leader in metabolomics.
- Applying this technology not only to hepatic diseases but also to other complex pathologies.
- Going from biotechnological research to commercialize new products and services.
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40
With this web OWL Genomics intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a qualified
physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 09/06/2010
This site complies with the HONcode standard for trustworthy health information:
verify here.